[Pharmacokinetics and clinical evaluations on aztreonam in perinatal infections in obstetrics and gynecology. A study of aztreonam in the perinatal co-research group]. 1990

S Matsuda, and K Oh, and H Hirayama, and T Shimizu, and K Sengoku, and H Haga, and R Inoue, and T Yamazaki, and H Mizoguchi, and Y Tori-i
Department of Obstetrics and Gynecology, Juntendo University School of Medicine, Kotoh Hospital.

Pharmacokinetics and clinical studies on an injectable monobactam antibiotic aztreonam (AZT), were carried out in perinatal infections in obstetrics and gynecology and the obtained results are summarized as follows. 1. Pharmacokinetic study (1) Upon one-shot intravenous injection of AZT 1 g before delivery, maternal serum concentration of AZT was 89.0 micrograms/ml immediately after the injection and a half-life (T 1/2) of 0.96 hour was observed. Umbilical-cord serum concentration showed a peak value of 16.5 micrograms/ml at 1.26 hours after the injection and gradually decreased with a T 1/2 of 1.91 hours. The transfer into amniotic fluid was observed and the peak value of AZT in amniotic fluid reached 12.9 micrograms/ml at 5.57 hours after the injection and slowly decreased thereafter with a T 1/2 of 4.42 hours. Transfer and disappearance in one-shot 2 g intravenous injection and 1 g intravenous drip infusion (1 hour) of AZT were very similar to the results obtained with the one-shot 1 g intravenous injection. (2) The residual serum concentration in neonates after one-shot 1 g intravenous injection of AZT to the mother was almost below the detectable limit. Transfer of AZT into milk was scarcely recognized. 2. Clinical studies (1) AZT was injected to 47 cases with various perinatal infections and it was more than "effective" in 45 cases with an efficacy rate of 95.7%. Also, all the 12 cases to which AZT was administered for prophylaxis of infections showed prophylactic effect. Bacterial eradication was obtained with 25 strains out of 29 aerobic Gram-negative bacteria, but 1 strain "persisted" and for 3 strains results were "unknown", hence an eradication rate of 96.2% was obtained. However, AZT treatment resulted in a little lower eradication rate against Gram-positive bacteria. (2) One case (1.3%) of minor degree of urticaria was found as a side effect, and one case each of eosinophilia and elevation of GOT, GPT and Al-P was observed as abnormal laboratory value. From the above results of pharmacokinetics and clinical evaluation, it has been concluded that AZT is a useful and highly safe drug in various perinatal infections and prophylaxis.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011251 Pregnancy Complications, Infectious The co-occurrence of pregnancy and an INFECTION. The infection may precede or follow FERTILIZATION. Complications, Infectious Pregnancy,Infectious Pregnancy Complications,Maternal Sepsis,Pregnancy, Infectious Complications,Sepsis during Pregnancy,Sepsis in Pregnancy,Infectious Pregnancy Complication,Pregnancy Complication, Infectious,Sepsis in Pregnancies,Sepsis, Maternal
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D005312 Fetal Blood Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery. Cord Blood,Umbilical Cord Blood,Blood, Cord,Blood, Fetal,Blood, Umbilical Cord,Bloods, Cord,Bloods, Fetal,Bloods, Umbilical Cord,Cord Blood, Umbilical,Cord Bloods,Cord Bloods, Umbilical,Fetal Bloods,Umbilical Cord Bloods
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S Matsuda, and K Oh, and H Hirayama, and T Shimizu, and K Sengoku, and H Haga, and R Inoue, and T Yamazaki, and H Mizoguchi, and Y Tori-i
December 1985, The Japanese journal of antibiotics,
S Matsuda, and K Oh, and H Hirayama, and T Shimizu, and K Sengoku, and H Haga, and R Inoue, and T Yamazaki, and H Mizoguchi, and Y Tori-i
September 1988, The Japanese journal of antibiotics,
S Matsuda, and K Oh, and H Hirayama, and T Shimizu, and K Sengoku, and H Haga, and R Inoue, and T Yamazaki, and H Mizoguchi, and Y Tori-i
December 1985, The Japanese journal of antibiotics,
S Matsuda, and K Oh, and H Hirayama, and T Shimizu, and K Sengoku, and H Haga, and R Inoue, and T Yamazaki, and H Mizoguchi, and Y Tori-i
December 1985, The Japanese journal of antibiotics,
S Matsuda, and K Oh, and H Hirayama, and T Shimizu, and K Sengoku, and H Haga, and R Inoue, and T Yamazaki, and H Mizoguchi, and Y Tori-i
April 1990, The Japanese journal of antibiotics,
S Matsuda, and K Oh, and H Hirayama, and T Shimizu, and K Sengoku, and H Haga, and R Inoue, and T Yamazaki, and H Mizoguchi, and Y Tori-i
March 1990, The Japanese journal of antibiotics,
S Matsuda, and K Oh, and H Hirayama, and T Shimizu, and K Sengoku, and H Haga, and R Inoue, and T Yamazaki, and H Mizoguchi, and Y Tori-i
March 1990, The Japanese journal of antibiotics,
S Matsuda, and K Oh, and H Hirayama, and T Shimizu, and K Sengoku, and H Haga, and R Inoue, and T Yamazaki, and H Mizoguchi, and Y Tori-i
August 1986, The Japanese journal of antibiotics,
S Matsuda, and K Oh, and H Hirayama, and T Shimizu, and K Sengoku, and H Haga, and R Inoue, and T Yamazaki, and H Mizoguchi, and Y Tori-i
December 1985, The Japanese journal of antibiotics,
S Matsuda, and K Oh, and H Hirayama, and T Shimizu, and K Sengoku, and H Haga, and R Inoue, and T Yamazaki, and H Mizoguchi, and Y Tori-i
December 1985, The Japanese journal of antibiotics,
Copied contents to your clipboard!